vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Quanterix Corp (QTRX). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $43.9M, roughly 1.4× Quanterix Corp). Quanterix Corp runs the higher net margin — -52.7% vs -70.9%, a 18.2% gap on every dollar of revenue. On growth, Quanterix Corp posted the faster year-over-year revenue change (24.7% vs 8.1%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-16.5M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 16.9%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Quanterix Corp is a life sciences firm that develops, manufactures, and commercializes ultra-sensitive single-molecule detection diagnostic platforms, reagents, and testing services. Its solutions empower biological research, drug development, and clinical diagnostics across oncology, neurodegenerative disorders, infectious diseases, and other therapeutic areas, serving research institutions, biopharmaceutical companies, and clinical laboratories globally.

CTKB vs QTRX — Head-to-Head

Bigger by revenue
CTKB
CTKB
1.4× larger
CTKB
$62.1M
$43.9M
QTRX
Growing faster (revenue YoY)
QTRX
QTRX
+16.6% gap
QTRX
24.7%
8.1%
CTKB
Higher net margin
QTRX
QTRX
18.2% more per $
QTRX
-52.7%
-70.9%
CTKB
More free cash flow
CTKB
CTKB
$14.8M more FCF
CTKB
$-1.8M
$-16.5M
QTRX
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
16.9%
QTRX

Income Statement — Q4 2025 vs Q4 2025

Metric
CTKB
CTKB
QTRX
QTRX
Revenue
$62.1M
$43.9M
Net Profit
$-44.1M
$-23.1M
Gross Margin
52.9%
45.7%
Operating Margin
-9.0%
-56.4%
Net Margin
-70.9%
-52.7%
Revenue YoY
8.1%
24.7%
Net Profit YoY
-557.1%
-98.8%
EPS (diluted)
$-0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
QTRX
QTRX
Q4 25
$62.1M
$43.9M
Q3 25
$52.3M
$40.2M
Q2 25
$45.6M
$24.5M
Q1 25
$41.5M
$30.3M
Q4 24
$57.5M
$35.2M
Q3 24
$51.5M
$35.8M
Q2 24
$46.6M
$34.4M
Q1 24
$44.9M
$32.1M
Net Profit
CTKB
CTKB
QTRX
QTRX
Q4 25
$-44.1M
$-23.1M
Q3 25
$-5.5M
$-33.5M
Q2 25
$-5.6M
$-30.0M
Q1 25
$-11.4M
$-20.5M
Q4 24
$9.6M
$-11.6M
Q3 24
$941.0K
$-8.4M
Q2 24
$-10.4M
$-7.4M
Q1 24
$-6.2M
$-11.2M
Gross Margin
CTKB
CTKB
QTRX
QTRX
Q4 25
52.9%
45.7%
Q3 25
52.7%
42.8%
Q2 25
52.3%
46.2%
Q1 25
48.6%
54.1%
Q4 24
58.5%
63.0%
Q3 24
56.3%
56.3%
Q2 24
54.6%
64.7%
Q1 24
51.3%
57.8%
Operating Margin
CTKB
CTKB
QTRX
QTRX
Q4 25
-9.0%
-56.4%
Q3 25
-17.6%
-92.8%
Q2 25
-23.3%
-151.6%
Q1 25
-36.1%
-86.9%
Q4 24
5.2%
-42.0%
Q3 24
-8.2%
-32.8%
Q2 24
-18.3%
-31.8%
Q1 24
-23.9%
-47.3%
Net Margin
CTKB
CTKB
QTRX
QTRX
Q4 25
-70.9%
-52.7%
Q3 25
-10.5%
-83.3%
Q2 25
-12.2%
-122.6%
Q1 25
-27.5%
-67.6%
Q4 24
16.8%
-33.1%
Q3 24
1.8%
-23.3%
Q2 24
-22.4%
-21.5%
Q1 24
-13.8%
-34.8%
EPS (diluted)
CTKB
CTKB
QTRX
QTRX
Q4 25
$-0.48
Q3 25
$-0.73
Q2 25
$-0.77
Q1 25
$-0.53
Q4 24
$-0.30
Q3 24
$-0.22
Q2 24
$-0.19
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
QTRX
QTRX
Cash + ST InvestmentsLiquidity on hand
$90.9M
$29.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$295.7M
Total Assets
$461.5M
$418.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
QTRX
QTRX
Q4 25
$90.9M
$29.8M
Q3 25
$93.3M
$38.3M
Q2 25
$75.5M
$132.9M
Q1 25
$95.3M
$76.5M
Q4 24
$98.7M
$56.7M
Q3 24
$162.3M
$29.3M
Q2 24
$177.9M
$47.0M
Q1 24
$168.8M
$45.3M
Stockholders' Equity
CTKB
CTKB
QTRX
QTRX
Q4 25
$341.7M
$295.7M
Q3 25
$378.6M
$314.5M
Q2 25
$377.6M
$292.5M
Q1 25
$379.6M
$316.4M
Q4 24
$395.7M
$330.0M
Q3 24
$385.5M
$338.9M
Q2 24
$389.1M
$340.8M
Q1 24
$392.6M
$343.4M
Total Assets
CTKB
CTKB
QTRX
QTRX
Q4 25
$461.5M
$418.8M
Q3 25
$494.9M
$444.1M
Q2 25
$493.3M
$375.6M
Q1 25
$482.6M
$396.5M
Q4 24
$499.5M
$406.5M
Q3 24
$491.2M
$411.0M
Q2 24
$483.7M
$415.9M
Q1 24
$492.1M
$414.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
QTRX
QTRX
Operating Cash FlowLast quarter
$-771.0K
$-16.4M
Free Cash FlowOCF − Capex
$-1.8M
$-16.5M
FCF MarginFCF / Revenue
-2.9%
-37.7%
Capex IntensityCapex / Revenue
1.6%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-80.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
QTRX
QTRX
Q4 25
$-771.0K
$-16.4M
Q3 25
$-3.9M
$-41.2M
Q2 25
$108.0K
$-5.7M
Q1 25
$-125.0K
$-13.9M
Q4 24
$2.0M
$-4.3M
Q3 24
$13.2M
$-5.7M
Q2 24
$6.2M
$-5.0M
Q1 24
$4.0M
$-20.2M
Free Cash Flow
CTKB
CTKB
QTRX
QTRX
Q4 25
$-1.8M
$-16.5M
Q3 25
$-4.6M
$-41.9M
Q2 25
$-1.5M
$-6.4M
Q1 25
$-974.0K
$-15.1M
Q4 24
$1.1M
$-4.7M
Q3 24
$12.2M
$-6.6M
Q2 24
$5.2M
$-6.5M
Q1 24
$3.4M
$-20.7M
FCF Margin
CTKB
CTKB
QTRX
QTRX
Q4 25
-2.9%
-37.7%
Q3 25
-8.7%
-104.2%
Q2 25
-3.2%
-26.3%
Q1 25
-2.3%
-49.9%
Q4 24
1.9%
-13.4%
Q3 24
23.7%
-18.4%
Q2 24
11.0%
-19.1%
Q1 24
7.6%
-64.5%
Capex Intensity
CTKB
CTKB
QTRX
QTRX
Q4 25
1.6%
0.2%
Q3 25
1.3%
1.7%
Q2 25
3.5%
3.2%
Q1 25
2.0%
4.1%
Q4 24
1.6%
1.2%
Q3 24
2.0%
2.4%
Q2 24
2.3%
4.7%
Q1 24
1.3%
1.6%
Cash Conversion
CTKB
CTKB
QTRX
QTRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
14.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

QTRX
QTRX

Products$29.2M67%
Consumable And Other Products$12.7M29%
Service Type Warranties$1.7M4%

Related Comparisons